Emfilermin

N/A

Report date: 2022/07/19 20:00:45

Base Information

Drug NameEmfilermin
Drug Alias NameAM 424rhLIFLIFRecombinant LIF protein - Ares-SeronoRecombinant leukaemia inhibitory factor protein - Ares-Serono +[9] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionLeukemia inhibitory factor receptor antagonists
TargetsLeukemia inhibitory factor receptor
Therapy Area/IndicationsInfertility, Female
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesWalter And Eliza Hall Institute Of Medical Research
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMerck KGaA, Darmstadt, Germany
Active IndicationsN/A
Inactive IndicationsInfertility, Female

Other Information

ATC CodeN/A
Related LinksDrugBank